Pathology Grand Rounds
Thursday, March 3rd 12:30-1:30pm

Hosted by: David Rimm, MD, PhD

Christina N. Curtis, PhD
Associate Professor of Medicine and Genetics,
Stanford University School of Medicine; Co-Director, Molecular Tumor Board, Stanford Cancer Institute

Towards Predictive Biomarkers in Early-Stage HER-2 Positive Breast Cancer

Needs: The talk will describe the use of several molecular technologies to characterize tumor heterogeneity and treatment response in early-stage HER-2 positive breast cancer. The speaker will outline the need for predictive biomarkers to guide treatment decision making in this setting. They will detail the application of spatial proteomic profiling to longitudinal tissue samples from a neoadjuvant-treated HER-2 positive clinical trial cohort and the identification of candidate predictive biomarkers.

Objectives: Understand the need for predictive biomarkers in early-stage HER2+ breast cancer; Understand how spatial proteomic profiling can be performed on clinical tissue samples; Understand how spatial proteomic profiling can inform biomarker discovery.

ZOOM LOGIN
Thursday, March 3rd 12:30-1:30pm
Hosted by: David Rimm, MD, PhD

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: Multiple Specialties, Pathology. Financial Disclosures: Christina Curtis, PhD, speaker to this educational event, is SAB member of GRAIL/Illumina; SAB Member licensed IP for Ravel Biotechnology; SAB Member for Resistance Bio, NanoString and Deep Cell and a consultant to Genetech. All of the relevant financial relationships listed for this individual have been mitigated. None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. This course will fulfill the licensure requirement set forth by the State of Connecticut.